<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774189</url>
  </required_header>
  <id_info>
    <org_study_id>020/CLARI-250/03</org_study_id>
    <nct_id>NCT00774189</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Clarithromycin 250mg Tablets Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Clarithromycin Formulations, Comparing Clarithromycin 250 mg Tablets of Ranbaxy Laboratories With Biaxin 250 mg Tablets of Abbott Laboratories in Healthy, Adult, Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to compare the single-dose oral bioavailability of&#xD;
      Clarithromycin 250 mg tablets of Ranbaxy Laboratories with Biaxin 250 mg tablets of Abbott&#xD;
      Laboratories in healthy, adult, human subjects under fasting conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open label, balanced, and randomized, two-treatment, two-period, two-sequence,&#xD;
      single-dose, crossover bioavailability study planned on 32 healthy, adult, human subjects&#xD;
      under fasting conditions. 31 subjects completed both the periods of the study. Both periods&#xD;
      were separated by a washout of twelve days The study was conducted on 32 healthy, adult,&#xD;
      human subjects under fasting conditions. 31 subjects completed both the periods of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clarithromycin 250 mg tablets of Ranbaxy Laboratories</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biaxin 250 mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin 250 mg tablets</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be in the age range of 18-45 years.&#xD;
&#xD;
          2. Be neither overweight nor underweight for his/her height as per the Life Insurance&#xD;
             Corporation of India height/weight chart for non-medical cases.&#xD;
&#xD;
          3. Have voluntarily given written informed consent to participate in this study.&#xD;
&#xD;
          4. Be of normal health as determined by medical history and physical&#xD;
&#xD;
          5. Examination of the subjects performed .within 14 days prior to the commencement of the&#xD;
             study.&#xD;
&#xD;
          6. If female and:&#xD;
&#xD;
        Of childbearing potential, is practicing an acceptable method of birth control for the&#xD;
        duration of the study as judged by the investigator(s), such as condoms, foams, jellies,&#xD;
        diaphragm, intrauterine device (IUD), or abstinence; or~ Is postmenopausal for at least 1&#xD;
        year; or Is surgically sterile bilateral tubal ligation, bilateral oophorectomy, or&#xD;
        hysterectomy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to clarithromycin, erythromycin and related macrolides&#xD;
&#xD;
          2. Any evidence of organ dysfunction or any clinically significant deviation from the&#xD;
             normal, in physical or clinical determinations.&#xD;
&#xD;
          3. Presence of disease markers of HIV 1 and 2, Hepatitis B and C viruses and syphilis&#xD;
             infection.&#xD;
&#xD;
          4. Female volunteers demonstrating a positive pregnancy screen.&#xD;
&#xD;
          5. Female volunteers who are currently breastfeeding.&#xD;
&#xD;
          6. Presence of values' which are clinically significantly different from normal reference&#xD;
             ranges for haemoglobin, total white blood cells count, differential WBC count and&#xD;
             platelet count&#xD;
&#xD;
          7. Positive for urinary screen testing of drugs of abuse (opiates and cannabinoids&#xD;
&#xD;
          8. Presence of values which are significantly different from normal.reference ranges (as&#xD;
             defined in Appendix 5) for se- rum creatinine, blood urea nitrogen serum aspartate&#xD;
             aminotransferase (AST), serum alanine aminotranferase (ALT), serum alkaline&#xD;
             phosphatase, serum billrubin, plasma glucose and serum cholesterol&#xD;
&#xD;
          9. Clinically abnormal chemical and microscopic examination of urine defined as presence&#xD;
             of RBC, WBC (&gt;4/HPF), epithelial cells (&gt;4/HPF), glucose, (positive) and protein&#xD;
             (positive).&#xD;
&#xD;
         10. History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary,&#xD;
             neurological or hematological disease, diabetes or glaucoma.&#xD;
&#xD;
         11. History of any psychiatric illness. which may impair the ability to provide written&#xD;
             informed consent.&#xD;
&#xD;
         12. Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining&#xD;
             from smoking for the duration of each study period.&#xD;
&#xD;
         13. History of drug dependence or excessive alcohol intake on a habitual basis of more&#xD;
             than 2 units of alcoholic beverages per day (1 'unit equivalent to half pint of beer&#xD;
             or 1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the&#xD;
             duration of each study period.&#xD;
&#xD;
         14. Use of any enzyme modifying drugs within 30 days prior to Day I of this study&#xD;
&#xD;
         15. Participation in any clinical trial within 12 weeks preceeding day 1 of study&#xD;
&#xD;
         16. Subjects who, through completion of this study, would have donated and/or lost more&#xD;
             than 350 mL of blood in past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ranbaxy Research Laboratories</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif monif</name_title>
    <organization>Ranbaxy Research Labs</organization>
  </responsible_party>
  <keyword>Bioequivalence clarithromycin 250mg tablets fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

